HBK Sorce Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

HBK Sorce Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Buy	+292	New	+$199K	﹤0.01%	594
2024 Q3	–	Sell	-194	Closed	-$204K	–	598
2024 Q2	$204K	Buy	+194	New	+$188K	0.01%	520
2021 Q1	–	Sell	-801	Closed	-$387K	–	555
2020 Q4	$387K	Sell	801 -135	-14%	-$72.9K	0.02%	322
2020 Q3	$524K	Sell	936 -202	-18%	-$122K	0.04%	250
2020 Q2	$710K	Buy	+1,138	New	+$646K	0.05%	204
2017 Q4	–	Sell	-451	Closed	-$202K	–	393
2017 Q3	$202K	Sell	451 -1	-0.2%	-$476	0.03%	304
2017 Q2	$222K	Buy	+452	New	+$198K	0.04%	277
2016 Q4	–	Sell	-511	Closed	-$205K	–	296
2016 Q3	$205K	Buy	+511	New	+$205K	0.04%	267

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Sorce Advisory's REGN Position: Q2 2026 in Review

HBK Sorce Advisory opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 292 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #594 among its holdings. This is a return to the name: HBK Sorce Advisory previously reported a position in REGN as recently as Q2 2024.

HBK Sorce Advisory first reported a position in REGN in Q3 2016 and has held it in 8 quarters since. The position peaked at $710K in Q2 2020. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

HBK Sorce Advisory held 292 shares of Regeneron Pharmaceuticals worth $225K as of Q2 2026.
Regeneron Pharmaceuticals was a new HBK Sorce Advisory position in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #594 holding.
HBK Sorce Advisory first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 8 quarters since.
HBK Sorce Advisory's Regeneron Pharmaceuticals position peaked at $710K in Q2 2020.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.